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Introduction {#sec001}
============

Every year, more than 10,000 people in the United States experience spinal cord injuries (SCI) due to trauma-related accidents. While medication regimens during the acute period of injury involve the extensive administration of steroids and other anti-inflammatory drugs, the recovery of neurologic function relies on the neural plasticity to each patient. The considerable number of patients that become permanently paralyzed despite medical intervention reflects the inadequacy of inherent mechanisms in repairing the nervous system \[[@pone.0230080.ref001], [@pone.0230080.ref002]\].

Bone marrow-derived mesenchymal stem/stromal cells (MSCs) are multipotent tissue stem cells that have shown promise in facilitating regeneration and/or recovery after neuronal injury \[[@pone.0230080.ref003]--[@pone.0230080.ref006]\]. We have previously demonstrated that xenografting human MSCs (hMSCs) into immunocompetent mice subjected to SCI \[[@pone.0230080.ref007]\] or brain ischemia \[[@pone.0230080.ref008]\] protected against short-term neurological deficits and damage; however, the levels of the grafted hMSCs decreased significantly within the first week. Further experiments indicated that hMSCs might communicate with recipient tissues and thereby convert the phenotypic polarization of host microglia/macrophages (MG/MΦ) to an alternatively activated phenotype (AAM), which is known to promote tissue repair and regeneration after injury \[[@pone.0230080.ref009]\]. Several immune- and nonimmune-related disease models and isogenic graft experiments have provided evidence for the immunomodulatory functions of hMSCs \[[@pone.0230080.ref010], [@pone.0230080.ref011]\]. However, precisely how hMSCs communicate with or regulate MG/MΦ remains unclear.

Chemokines guide the migration of immune cells, such as leukocytes and macrophages, and stimulate inflammatory responses, and are divided into the CC, CXC, C, and CX3C families from the structural feature \[[@pone.0230080.ref012]\]. Levels of many chemokines are increased in patients with central nervous system (CNS) disorders, such as SCI \[[@pone.0230080.ref013]\] and cerebral infarction \[[@pone.0230080.ref014]\], increase the levels of many chemokines. Indeed, enhanced levels of chemokines were observed in isogenic grafted bone marrow-derived MSCs of a hypoxia-ischemia rat model, but not in adipose tissue-derived MSCs \[[@pone.0230080.ref015]\]. Cultured hMSCs secrete several chemokines and express several chemokine receptors on the cell surface \[[@pone.0230080.ref016]\]. An additional study further reported that MSCs elevate the secretion of several chemokines by stimulating lipopolysaccharide (LPS) *in vitro* \[[@pone.0230080.ref017]\]. Hence, the communication between hMSCs and MG/MΦ may be partially mediated by chemokines.

Research has indicated that some chemokines play other roles in addition to chemotaxis response. Chemokines such as CCL2 (monocyte chemoattractant protein-1; MCP-1), CX3CL1 (fractalkine), CXCL12 (Stromal cell-derived factor 1; SDF-1), and CCL5 (regulated on activation, normal T cell expressed and secreted; RANTES) are reportedly involved in neuroprotection \[[@pone.0230080.ref018]--[@pone.0230080.ref021]\], axonal regeneration \[[@pone.0230080.ref022], [@pone.0230080.ref023]\], and the differentiation of MG/MΦ to AAM \[[@pone.0230080.ref024]\].

In present study, we firstly examined the effect and fate of transplanted hMSCs after SCI. Following the study, we determined gene expression for selected some MG/MΦ-related chemokines and their receptors on SCI, and then focused on two representative major MG/MΦ-related chemokine axes, CCL2/CCR2 and CCL5/CCR5, whose corresponding increases in the gene expression had been characterized as acute or chronic. The influences of hMSC implantation following SCI on the CCL2/CCR2 and CCL5/CCR5 axes, inflammation, MG/MΦ polarization, and/or axonal regeneration were examined to gain insight into the actions of hMSCs.

Materials and methods {#sec002}
=====================

Animals {#sec003}
-------

Wild-type, male C57BL/6 mice (8 to 12 weeks old, weighing 17 to 25 g) were purchased from Sankyo Lab Service Corporation (Tokyo, Japan) and used for the experiments (total of 139 animals including 7 euthanized animals). Mice were maintained on a 12-h light/dark cycle at 24 ± 2° C with constant humidity (55 ± 10%) and free access to food and water. All experimental procedures involving animals were approved and followed by and conducted in accordance with the guidelines of the Institutional Animal Care and Use Committee of Showa University (\#06105 and 07079).

SCI model {#sec004}
---------

The SCI mouse model was generated in accordance with previously described methods \[[@pone.0230080.ref007], [@pone.0230080.ref025]\]. Anesthesia was induced via inhalation of 4.0% sevoflurane and maintained with 3.0% sevoflurane in N~2~O/O~2~ (2:1). Under aseptic conditions, an incision was made along the midline of the skin on the back, and the muscles, soft tissues, and yellow ligaments overlying the spinal column between T9 and T10 were removed. The intervertebral spinal cord between T9 and T10 was then transected with a thin-bladed razor (FEATHER, Osaka, Japan). After bleeding had stopped and the coagulated blood had been removed, the incision was closed, and the animals were administered 1.0 mL of lactated Ringer's solution (s.c.; Otsuka, Tokyo, Japan) to prevent dehydration of which were given once a day until they gain the body weight. To support their eating, animal food was placed on the cage floor, and the water bottle was lowered to allow easy access. Moreover, to support urination, the region of the lower abdomen in all mice was gently stimulated a few times every day. Although we did not administer any pain relievers or anesthesia during the experiments because they may influence SCI and locomotor activity, we made all efforts to minimize animal numbers and animal discomfort. However, total of 7 animals were excluded from the study by humane endpoints. The 3-animals scored the Basso Mouse Scale (BMS) \[[@pone.0230080.ref026]\] more than 3 immediately after SCI were excluded from the experiments for incomplete hindlimb paralysis by a surgical error. Moreover, the 4-mice were excluded from the study because the mice exhibited peritoneal infection, severe body weight loss more than 25% before surgery, hindlimb wounds, and/or tail or foot autophagia. These animals were euthanized by cervical dislocation or CO~2~-gas exposure.

Preparation of implanted hMSCs {#sec005}
------------------------------

Frozen vials of hMSCs from the bone marrow were obtained from Dr. Prockop (The Center for the Preparation and Distribution of Adult Stem Cells \[<http://medicine.tamhsc.edu/irm/msc-distribution.html>\]) under the auspices of a National Institutes of Health (NIH)/National Center for Research Resources grant (P40 RR 17 447--06). The experiments were performed with hMSCs from donor 281L \[[@pone.0230080.ref007], [@pone.0230080.ref008], [@pone.0230080.ref027]\]. To expand hMSCs, a frozen vial of 1.0×10^6^ passage 3 cells was thawed and plated at 100 cells/cm^2^ in multiple 150-mm plates (Nunclon, Thermo Fisher Scientific, Waltham, MA) with a 20-mL complete culture medium (CCM) that consisted of α-minimal essential medium (α-MEM; Invitrogen, Carlsbad, CA), 20% heat-inactivated fetal bovine serum (FBS; Hyclone; Thermo Fisher Scientific), 100 units/mL penicillin, 100 μg/mL streptomycin (Invitrogen), and 2 mM L-glutamine (Invitrogen). The cultures were incubated, and the medium was replaced every 3 days for approximately 8 days until the cells were 70--80% confluent. The medium was then discarded, and the culture plates were washed with phosphate-buffered saline (PBS). Adherent cells were harvested using 0.25% trypsin and 1 mM EDTA (Invitrogen) for 5 min at 37° C and resuspended at 5 × 10^5^ cells in 0.5 μL of sterile Hank's balanced salt solution (HBSS; Invitrogen) for injection.

Injection of hMSCs into the spinal cord {#sec006}
---------------------------------------

The hMSCs were injected into the spinal cord in accordance with previously described methods \[[@pone.0230080.ref007]\]. Briefly, on the day following surgery to induce SCI, mice were re-anesthetized via inhalation of sevoflurane. The animals were placed face-down, and a truncated 29G needle with a 5.0-μL glass syringe (Hamilton, Reno, NV) was inserted directly into the intervertebral spinal cord (D/V -1.0 mm) between T10 and T11. We trained investigators to insert the needle to the depth of the anterior horn of the spinal cord by the injection of dye. Then, the depth of needle insertion was standardized at -1.0 mm from surface of which did not leak the dye from the needle tract during infusion or from the ventral spinal cord. The hMSCs (5 × 10^5^ cells/μL, n = 40 mice) or HBSS (n = 26 mice) was infused at a rate of 0.5 μL/min with an Ultra Micro Pump (World Precision Instruments, Sarasota, FL). Following infusion, the needle was left in place for 1 min to facilitate the diffusion of the solution into the tissue. Previously, we demonstrated that the fate of hMSCs does not differ between immunocompetent and immunodeficient animals after ischemia \[[@pone.0230080.ref008]\]. Therefore, in the present study, we refrained from using immunosuppressant following cell implantation \[[@pone.0230080.ref010]\].

Assessment of motor function {#sec007}
----------------------------

Motor function after SCI was evaluated using an open-field behavior test that focused on hindlimb locomotor function according to the BMS. The BMS consists of an open-field locomotor rating scale that ranges from 0 (complete paralysis) to 9 (normal mobility). Briefly, individual mice were placed in the center of an open field (50 × 50 cm^2^) with a smooth, non-slip floor and monitored for 4 min. Hindlimb movements, trunk/tail stability, and forelimb-hindlimb coordination were assessed and graded. Mice were tested daily for 14 days after the operation. Mice were randomly numbered to ensure that the investigators remained unaware of the treatment groups during scoring.

Isolation of RNA and production of cDNA {#sec008}
---------------------------------------

Under sodium-pentobarbital (100 mg/kg, i.p.) anesthesia, spinal cord samples from the T7 to T12 vertebrae were dissected on postoperative days (pod) 0 (sham-operated non-SCI control), 1, 3, 7, and 14 with/without hMSC or vehicle injection. The tissue was snap-frozen in liquid nitrogen and stored at −80° C until use. Total RNA was isolated using the TRIZOL Reagent (Invitrogen) in accordance with the manufacturer's instructions and dissolved in RNase-free water. The purity and concentration of the extracted RNA were determined spectrophotometrically (NanoDrop, Wilmington, DE). A High-Capacity RNA-to-cDNA Kit (Applied Biosystems, Foster City, CA) was used to synthesize cDNA using 2 μg of total RNA in accordance with the manufacturer's instructions. To confirm the species specificity of the primers, we also extracted total RNA from cultured hMSCs and synthesized the cDNA.

Semi-quantification of the number of hMSCs in the spinal cord {#sec009}
-------------------------------------------------------------

On days 1, 3, or 14 after SCI (0, 2, or 13 days after cell injection; n = 4 mice at each time-point), mice were anesthetized with sodium pentobarbital (100 mg/kg, i.p.), and the spinal cord was collected and subjected to cDNA preparation as described above. Semi-quantification of the number of hMSCs was determined based on the gene expression level of human *GAPDH* in mouse *Gapdh* via qPCR. Standard curves were generated by adding serial dilutions of hMSCs (1 × 10^2^ to 1 × 10^6^ cells) to spinal cord samples (T7 to T12 vertebrae) of uninjured mice prior to homogenization according to the methods published by previous studies \[[@pone.0230080.ref007], [@pone.0230080.ref008], [@pone.0230080.ref028]--[@pone.0230080.ref030]\]. Finally, the estimated number of resident hMSCs was calculated from the standard curve. The human-specific primers cross-hybridized less than 0.07% with mouse cDNA obtained from spinal cord samples that had not been injected with hMSCs.

Polymerase chain reaction (PCR) {#sec010}
-------------------------------

PCR analyses were performed using TaKaRa Ex Taq (TaKaRa, Shiga, Japan) to confirm the species specificity of primers. The reaction mixture was created with an appropriate volume of the cDNA mixture: 0.25 μL of forward and reverse primers (50 nmol/mL), 2.0 μL of dNTP mixture (0.25 mM each), 0.1 μL of TaKaRa Ex Taq (5 units/μL), and 2.0 μL of 10 × Ex Taq Buffer in a total volume of 20 μL. Thermal-cycling parameters were set as follows: 95° C for 1 min for initial denaturation, followed by a cycling regime of 40 cycles at 95° C for 45 s, 60° C for 30 s, and 72° C for 45 s. At the end of the final cycle, an additional 7-min extension step was conducted at 72° C. Ten microliters of each reaction mixture was electrophoresed onto 2.0% agarose gel, and the bands were visualized using ethidium bromide.

Quantitative PCR (qPCR) analyses were performed with SYBR Premix Ex Taq II reagent (TaKaRa) and an Applied Biosystems 7900HT Fast Real-Time PCR System (Applied Biosystems, Lincoln, CA). Relative gene expression was calculated using the absolute quantification method. The mouse glyceraldehyde-3-phosphate dehydrogenase gene (*Gapdh*) was used as a housekeeping gene to normalize the cDNA levels. All primers were designed as described in [Table 1](#pone.0230080.t001){ref-type="table"}. All data are expressed the relative level (fold) to compare with pod 0 (basal level) after normalization against *mouse Gapdh* as a housekeeping gene (n = 6 mouse at each time-point).

10.1371/journal.pone.0230080.t001

###### Primers used for real-time polymerase chain reaction.

![](pone.0230080.t001){#pone.0230080.t001g}

  Name      Symbol      Species   Forward (5′ to 3′)            Reverse (5′ to 3′)          Size (bp)
  --------- ----------- --------- ----------------------------- --------------------------- -----------
  AIF1      *Aif1*      mouse     `atcaacaagcaattcctcgatga`     `cagcattcgcttcaaggacata`    144
  Arg1      *Arg1*      mouse     `ctccaagccaaagtccttagag`      `aggagctgtcattagggacatc`    185
  CCL2      *Ccl2*      mouse     `ttaaaaacctggatcggaaccaa`     `gcattagcttcagatttacgggt`   121
  CCL3      *Ccl3*      mouse     `ttctctgtaccatgacactctgc`     `cgtggaatcttccggctgtag`     100
  CCL4      *Ccl4*      mouse     `ttcctgctgtttctcttacacct`     `ctgtctgcctcttttggtcag`     121
  CCL5      *Ccl5*      mouse     `gctccaatcttgcagtcgtg`        `gagcagctgagatgcccatt`      242
  CCL7      *Ccl7*      mouse     `gctgctttcagcatccaagtg`       `ccagggacaccgactactg`       135
  CCR1      *Ccr1*      mouse     `tggtgggcaatgtcctagtg`        `aagtaacagttcgggccctc`      300
  CCR2      *Ccr2*      mouse     `atccacggcatactatcaacatc`     `caaggctcaccatcatcgtag`     104
  CCR3      *Ccr3*      mouse     `accccgtacaacctggttct`        `ccaacaaaggcgtagattactgg`   158
  CCR5      *Ccr5*      mouse     `ttttcaagggtcagttccgac`       `ggaagaccatcatgttacccac`    158
  CRMP2     *Dpysl2*    mouse     `tcaaaggtggcaagattgtgaa`      `ggaatcaccattctggagtgg`     145
  CXCL1     *Cxcl1*     mouse     `ctgggattcacctcaagaacatc`     `cagggtcaaggcaagcctc`       117
  CXCL2     *Cxcl2*     mouse     `tccagagcttgagtgtgacg`        `tggttcttccgttgagggac`      201
  CXCR2     *Cxcr2*     mouse     `gggtggggagttcgtgtaga`        `aggtgctaggatttgagcct`      200
  ELANE     *Elane*     mouse     `caggaacttcgtcatgtcagc`       `agcagttgtgatgggtcaaag`     162
  ENO2      *Eno2*      mouse     `tgagaataaatccttggagctggt`    `ggtcatcgcccactatctgg`      302
  GAP43     *Gap43*     mouse     `tctgctactaccgatgcagc`        `tggaggacggggagttatcag`     181
  GAPDH     *Gapdh*     mouse     `gctacactgaggaccaggttgt`      `ctcctgttattatgggggtctg`    306
  GAPDH     *Gapdh*     human     `ggagcgagatccctccaaaat`       `ggctgttgtcatacttctcatgg`   197
  GAPDH\*   *Gapdh*     mouse     `aggtcggtgtgaacggatttg`       `tgtagaccatgtagttgaggtca`   123
  IL-1β     *Il1b*      mouse     `gcaactgttcctgaactcaact`      `atcttttggggtccgtcaact`     89
  IL-4      *Il4*       mouse     `tctcgaatgtaccaggagccatatc`   `agcaccttggaagccctacaga`    183
  MCPIP     *Zc3h12a*   mouse     `acgaagcctgtccaagaatcc`       `taggggcctctttagccaca`      115
  MPO       *Mpo*       mouse     `agggccgctgattatctacat`       `ctcacgtcctgataggcaca`      152
  Ym-1      *Chil3*     mouse     `ggtggacacagaatggttcttc`      `ccaggagcgttagtgacagc`      128

AIF: allograft inflammatory factor, Arg: arginase, CCL: chemokine (C-C motif) ligand, CCR: chemokine (C-C motif) receptor, Chil: chitinase-like, CRMP: collapsin response mediator protein, CXCL: chemokine (C-X-C motif) ligand, CXCR: chemokine (C-X-C motif) receptor, ELANE: neutrophil elastase, Eno: neuron-specific enolase, GAP: growth associated protein, GAPDH: glyceraldehyde-3-phosphate dehydrogenase, GFAP: glial fibrillary acidic protein, IL: interleukin, MCPIP: monocyte chemotactic protein-1 induced protein, MPO: myeloperoxidase, \* = not species specific.

Immunostaining {#sec011}
--------------

Under sodium-pentobarbital (100 mg/kg, i.p.) anesthesia, the animals were transcardially perfused with 0.9% saline followed by 2% paraformaldehyde (PFA) in 50 mM phosphate buffer (PB) (pH 7.2), and the spinal cord (T7 to T12 vertebrae) was carefully removed. The spinal cords were then post-fixed overnight, immersed in 20% sucrose in 0.1 M PB for two nights, and embedded in liquid nitrogen-cooled isopentane using an embedding solution (20% sucrose in 0.1 M PB:O.C.T. compound \[Sakura Finetech, Tokyo, Japan\]: 2:1\]. Sagittal spinal cord sections (thickness, 5 μm) were obtained using a cryostat (Hyrax50, Carl Zeiss, Inc.; Oberkochen, Germany) and stored at --80° C until use.

For single staining, the sections were washed with PBS and incubated in 0.3% H~2~O~2~ to quench internal peroxidase reactions. The sections were then immersed in 2.5% normal horse serum (NHS; Vector, Burlingame, CA) in PBS containing 0.05% Tween 20 (PBST) to block non-specific reactions for 1 h. Subsequently, the sections were incubated overnight with polyclonal rabbit anti-GFAP (1:10; DAKO, Glostrup, Denmark) or polyclonal rabbit anti-Iba1 antibodies (1:500; WAKO, Tokyo, Japan). After washing with PBST, the sections were incubated with biotinylated goat anti-rabbit immunoglobulin G (IgG) (1:200, Santa Cruz, Santa Cruz, CA) for 2 h. They were then incubated in an avidin-biotin complex solution (Vector) followed by diaminobenzidine (DAB; Sigma, St. Louis, MO) as a chromogen. Immunopositive cells were observed via light microscopy (AX70) using DP2-BSW image analysis software (Olympus, Tokyo, Japan).

For multiple staining, sections that had been immersed in 0.3% H~2~O~2~ were incubated with an M.O.M. Immunodetection Kit (Vector), followed by 2.5% NHS/PBST. The sections were then incubated overnight with primary antibodies. The sections were rinsed with PBST and immersed with appropriate fluorescently labeled secondary antibodies for 2 h. Subsequently, cell nuclei were stained with 4,6-diamidine-2-phenylindole dihydrochloride (DAPI, 1:10,000; Roche, Manheim, Germany) and incubated in 1.0 mM CuSO~4~ in 50 mM ammonium acetate buffer (pH 5.0) to diminish autofluorescence \[[@pone.0230080.ref031]\]. Fluorescence was detected using an Axio Imager optical sectioning microscope with ApoTome (Carl Zeiss, Inc.). All primary and secondary antibodies used for immunostaining are listed in Tables [2](#pone.0230080.t002){ref-type="table"} and [3](#pone.0230080.t003){ref-type="table"}. For control staining, the same steps were performed with the exception of incubation with each primary antibody.

10.1371/journal.pone.0230080.t002

###### Primary antibodies used for immunohistochemistry.
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  Primary antibodies (Clone \#)   Host     Companies                                      Catalog \#   Dilution
  ------------------------------- -------- ---------------------------------------------- ------------ ----------
  CCL2                            Rabbit   Bioss (Boston, MA)                             bs-1101R     1,500
  CCL5 (25H14L17)                 Rabbit   Thermo Fisher Scientific (Waltham, MA)         701030       100
  CCL5                            Goat     R&D systems (Minneapolis, MN)                  AF478        300
  CCR2                            Goat     Novus Biologicals (Littleton, Co)              NB100-701    300
  CCR2                            Goat     GeneTex (Irvine, CA)                           GTX45788     300
  CCR5                            Rabbit   Bioss (Boston, MA)                             bs-2514R     500
  NeuN (A60)                      Mouse    Merc Millipore (Burlington, MA)                MAB377       1,000
  GFAP                            Rabbit   DAKO (Glostrup, Denmark)                       N1506        10
  GFAP (G-A-5)                    Mouse    SIGMA (St. Louis, MO)                          G3893        1,000
  Iba1                            Rabbit   Wako (Osaka, Japan)                            019--19741   500
  Alexa635labeled-Iba1            Rabbit   Wako (Osaka, Japan)                            013--26471   500
  F4/80 (Cl:A3-1)                 Rat      BMA Biomedicals (Augst, Switzerland)           T-2008       500
  Ly-6G (RB6-8C5)                 Rat      BD Biosciences (Franklin Lakes, NJ)            557445       400
  iNOS                            Rabbit   Merc Millipore (Burlington, MA)                06--573      250
  Ym-1                            Rabbit   StemCell Technologies (Vancouver, BC Canada)   1404         200
  CRMP2                           Rabbit   LifeSpan BioSciences (Seattle, WA)             LS-B5657     3,000
  GAP43 (EP890Y)                  Rabbit   Abcam (Cambridge, UK)                          ab75810      500

CCL: chemokine (C-C motif) ligand, CCR: chemokine (C-C motif) receptor, CRMP: collapsin response mediator protein, GAP: growth associated protein, GFAP: glial fibrillary acidic protein, Iba1: ionized calcium-binding adapter molecule, iNOS: inducible nitric oxide synthase, NeuN: neuronal nuclei.

10.1371/journal.pone.0230080.t003

###### Secondary antibodies used for immunohistochemistry.
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  Secondary antibodies     Host     Companies                                   Catalog \#    Dilution
  ------------------------ -------- ------------------------------------------- ------------- ----------
  Rabbit IgG (biotin)      Goat     Santa Cruz Biotechnology (Santa Cruz, CA)   SC-2040       200
  Goat IgG (biotin)        Horse    Vector Laboratory (Burlingame, CA)          BA-9500       200
  Mouse IgG (Alexa 546)    Goat     ThermoFisher Scientific (Waltham, MA)       A11030        800
  Rabbit IgG (Alexa 488)   Goat     ThermoFisher Scientific (Waltham, MA)       A11034        400
  Rabbit IgG (Alexa 546)   Goat     ThermoFisher Scientific (Waltham, MA)       A11035        400
  Rabbit IgG (Alexa 647)   Goat     ThermoFisher Scientific (Waltham, MA)       A21245        400
  Rat IgG (FITC)           Goat     Jackson ImmunoResearch (West Grove, PA)     112-096-071   200
  Goat IgG (Alexa FITC)    Donkey   ThermoFisher Scientific (Waltham, MA)       A11055        400
  Goat IgG (Alexa 546)     Donkey   ThermoFisher Scientific (Waltham, MA)       A1056         400

Cell counting {#sec012}
-------------

Five sagittal sections (thickness: 5 μm) were collected from each mouse: at the midline (3), which included the central canal adjacent to the core injury site; and bilaterally at 150 μm (2 and 4) and 300 μm (1 and 5) lateral to the midline. The numbers of immunopositive cells against CCR2, Iba1, Ly-6G, and inducible nitric oxide (iNOS) antibodies were counted in four random fields at the injury site in each animal at 500× magnification and expressed as the average total number in a square millimeter (mm^2^).

Injection of recombinant mouse CCL5 (RANTES) into the spinal cord {#sec013}
-----------------------------------------------------------------

To investigate the role of CCL5 in the spinal cord after injury, recombinant mouse CCL5 was directly injected into the spinal cord between T10 and T11 according to the cell-injection procedure described above. Recombinant mouse CCL5 (RANTES; Miltenyi Biotec, Bergisch Gladbach, Germany) was dissolved in saline containing 0.1% bovine serum albumin (BSA; Wako) under aseptic conditions to obtain a concentration of 20 ng/μL. Seven days after SCI, mouse spinal cords were injected with a bolus of CCL5 (20 ng, n = 6 mice) or vehicle (n = 6 mice) at a rate of 0.5 μL/min. Mice were anesthetized with sodium pentobarbital (100 mg/kg, i.p.) at 24 h following injection, and spinal cord tissue was dissected from T7 to T12 for qPCR.

Statistical analysis {#sec014}
--------------------

As each mouse was assigned a random number, all data were collected and analyzed without the investigator being aware of the group identities. Data are expressed as the mean ± standard error of the mean (SEM). Statistical comparisons were conducted with one-way analyses of variance (ANOVAs) following non-parametric multiple comparisons, as indicated in each figure legend. A value of *P \< 0*.*05* was considered to indicate statistical significance. Analyses were performed using Statcel4 (OMS Ltd., Tokyo, Japan).

Results {#sec015}
=======

Injection of hMSCs suppressed SCI symptoms {#sec016}
------------------------------------------

We have previously reported that transplant viable hMSCs, but not inviable hMSCs into injured spinal cord significantly improved locomotor activity and decreased lesion size which is surrounded by GFAP immunoreactions within a week \[[@pone.0230080.ref007]\]. These effects were likely mediated through MG/MΦ-hMSC communication. To confirm the reproducibility of these findings, we determined the BMS score, the damaged site by performing GFAP immunostaining and assessing the gene expression of *Eno2* (neuron-specific enolase) as well as the retention of hMSCs in the spinal cord ([Fig 1](#pone.0230080.g001){ref-type="fig"}).

![Injection of human mesenchymal stem/stromal cells (hMSCs) suppresses spinal cord injury (SCI) symptoms.\
**(A)** Retention of hMSCs after injection into the spinal cord 1 day after SCI (n = 4 mouse at each time-point). \*\*: *P \< 0*.*01* (Dunnett's *post hoc* test, *vs* day 1). **(B)** Locomotor activity was determined based on BMS scores after SCI with/without hMSC injection. We injected hMSCs (filled circles, n = 40 mouse) or vehicle (HBSS; open circles, n = 26 mouse) into the spinal cord on postoperative day (pod) 1. Locomotor activity was then tracked for 14 days. Control animals (filled triangle, n = 45 mouse) received no injection into the spinal cord after SCI. \*: *P \< 0*.*05*, \*\*: *P \< 0*.*01* (Tukey's *post hoc* test). **(C)** Representative images of lesion site in the spinal cord 3 and 14 days after SCI (n = 3 mouse in each group). The lesion site was identified as the area surrounded by enhanced GFAP expression. Vehicle-treated control animals (upper) exhibited a larger lesion area than hMSC-treated animals (bottom). R: rostral, C: caudal, D: dorsal, V: ventral. **(D)** Expression of *Eno2* was quantified via real time-PCR after SCI with/without hMSCs in a time-dependent fashion. *Eno2* expression was temporarily decreased on pod 3 in the HBSS-treated group (n = 5 mouse). Significant suppression of *Eno2* expression was observed in the hMSC-treated group (n = 10 mouse) on pod 3. \*\*: *P \< 0*.*01* (Dunnett's *post hoc* test), n.s.: not significant. The gene expression levels are expressed the relative level (fold) to compare with pod 0 (basal level, n = 6 mouse) after normalization against *Gapdh* as a housekeeping gene. All data are expressed as the mean ± SEM.](pone.0230080.g001){#pone.0230080.g001}

On day 1 after SCI, hMSCs (5 × 10^5^ cells/μL) or HBSSs were injected into the intervertebral spinal cord. To validate the injection and retention of the hMSCs, human *GAPDH* was semi-quantified via qPCR, and the estimated hMSC number was calculated from the standard curve ([Fig 1A](#pone.0230080.g001){ref-type="fig"}). Immediately after hMSC injection (pod 1), approximately 260,000 hMSCs were detected--representing 50% of the injected cells--at the five vertebral sites (Th 7--12), including the site of injection. The numbers of hMSCs decreased to approximately 40,000 cells on pod 3, and have few-to-no hMSCs were detected on pod 14.

SCI induced severe locomotor disability, with BMS scores reaching approximately 1.5 points within a few hours; they gradually increased through pod 14. Animals treated with hMSCs were associated with significantly higher BMS scores than were the vehicle-treated animals from pod 3 through pod 14 ([Fig 1B](#pone.0230080.g001){ref-type="fig"}). Typical images of the lesion sites surrounded by GFAP immunoreactions in the hMSC-treated and HBSS-treated groups on pod 3 and 14 are shown in [Fig 1C](#pone.0230080.g001){ref-type="fig"}. The hMSC-treated mice exhibited fewer lesions (i.e., glial scarring) than the HBSS-treated mice at pod 14.

Eno2 is a neuron-specific glycolytic enzyme which is considered to indicate neuronal viability. Expression of *Eno2* was significantly higher in hMSC-treated animals than in HBSS-treated animals ([Fig 1D](#pone.0230080.g001){ref-type="fig"}). All of these results support the findings of our previous study \[[@pone.0230080.ref007]\]: hMSCs suppress SCI-induced adverse events.

Expression of chemokines and their receptors after SCI {#sec017}
------------------------------------------------------

We next quantified the levels of MG/MΦ-related chemokines and the expression of their receptor genes in mice during the experimental periods without hMSC injection after the SCI ([Fig 2](#pone.0230080.g002){ref-type="fig"}). The expression of selected chemokine genes, including *Ccl2*, *Ccl3*, *Ccl4*, *Ccl7*, *Cxcl1*, and *Cxcl2*, significantly increased by 48-, 41-, 228-, 52-, 17-, and 56-fold, respectively, on pod 1. With the exceptions of *Ccl3*, *Ccl4*, and *Cxcl1*, decreases in gene expressions were mostly observed on pod 7. Levels of *Ccl3*, *Ccl4*, and *Cxcl1* expression remained 41-, 112-, and 7-fold greater than pre-injury levels on pod 14. Although no increases in *Ccl5* expression were observed during the acute period, levels of *Ccl5* expression had increased by 82-fold on pod 14. By contrast, the expression of all chemokine receptors, including *Ccr1*, *Ccr2*, *Ccr3*, *Ccr5*, and *Cxcr2* significantly increased by 12-, 44-, 6-, 4-, and 144-fold, respectively, on pod 1. Although *Ccr1*, *Ccr3*, and *Cxcr2* expression decreased on pod 7, *Ccr2* and *Ccr5* levels remained 18-fold and 5-fold greater, respectively, at pod 14. We divided these chemokines into two groups: those exhibiting acute increases following SCI (CCL2, CCL3, CCL4, CCL7, CXCL1, and CXCL2) and those exhibiting increases in the chronic phase after SCI (CCL5). Then, we further analyzed the cellular localization of CCL2 and CCL5 and their receptors in the spinal cord via immunohistochemistry because they have been reported well for MG/MΦ migration as a representative gene.

![Gene expression of chemokines and their receptors after spinal cord injury (SCI).\
Expression of *Ccl2* **(A)**, *Ccl3* **(B)**, *Ccl4* **(C)**, *Ccl7* **(E)**, *Cxcl1* **(F)**, and *Cxcl2* **(G)** significantly increased on post-operative day (pod) 1. In contrast, increases in *Ccl5* **(D)** expression were observed on pod 14. Increases in gene expression were observed for all chemokine receptors **(H---L)** on pod 1. While *Ccr1* **(H)**, *Ccr3* **(J)**, and *Cxcr2* **(L)** expression decreased by pod 7, *Ccr2* **(I)** and *Ccr5* **(K)** levels remained significantly elevated on pod 14. All data are expressed the relative level (fold) to compare with pod 0 (basal level) after normalization against *Gapdh* as a housekeeping gene (n = 6 mouse at each time-point). Data are expressed as mean ± SEM. \*: *P\<0*.*05*, \*\*: *P\<0*.*01* (Dunnett's *post hoc* test, *vs* day 0).](pone.0230080.g002){#pone.0230080.g002}

Distribution of CCL2 and CCR2 expression in the spinal cord on day 1 {#sec018}
--------------------------------------------------------------------

We examined the cellular localization of CCL2 and its receptor CCR2 via immunohistochemistry before inducing SCI and at pods 1 and 14 after SCI. Few-to-no CCL2 immunoreactions were observed in the spinal cord of pre-SCI mice. Immunopositive reactions for CCL2 were observed around the site of SCI at pod 1. CCL2 immunoreactions at pod 1 merged with NeuN (a neuronal marker) but not with GFAP (an astrocytic marker) or F4/80 (an MG/MΦ marker) ([Fig 3A and 3B](#pone.0230080.g003){ref-type="fig"}). Similar to the findings observed for *Ccl2* expression ([Fig 2A](#pone.0230080.g002){ref-type="fig"}), CCL2 immunoreactivity had diminished by pod 14 ([Fig 3C](#pone.0230080.g003){ref-type="fig"}).

![Localization of CCL2 and CCR2 after spinal cord injury (SCI).\
**(A)** CCL2^+^ cells (*green*) were observed around the site of SCI on day 1 and were merged with the neuronal marker NeuN (*red*) (arrows). **(B)** CCL2^+^ immunoreactions (*green* with arrows) did not overlap with the astrocyte marker GFAP (uppe*r* in *red*) or the MG/MΦ marker F4/80 (bottom in *red*). **(C)** The intensity of CCL2^+^ immunoreactivity decreased by postoperative day (pod) 14. **(D)** CCR2^+^ immunoreactivity (*green*) was mainly expressed in Ly-6G^+^ cells (*pink*) around the site of the spinal cord lesion (arrows), but not in Iba1^+^ cells (*red*) (arrowhead). **(E)** Numbers of CCR2^+^, Ly-6G^+^, Iba1^+^, and merged cells were counted at the site of injury (n = 5 mouse). Data are expressed as the mean ± SEM. \*\*: *P\<0*.*01* (Dunnett's *post hoc* test). **(F)** Many CCR2^+^ (*green*)/Ly-6G+ (*pink*) cells were also merged with iNOS (*red*) (arrows). **(G)** Numbers of CCR2^+^, Ly-6G^+^, iNOS^+^, and merged cells were counted (n = 5 mouse). Most CCR2^+^ cells were co-stained with Ly-6G and iNOS. Data are expressed as the mean ± SEM. *Blue* indicates nuclear staining with DAPI.](pone.0230080.g003){#pone.0230080.g003}

Few-to-no CCR2 immunoreactions were observed in the spinal cord pre-SCI. However, immunoreactivity was obviously recognized at the epicenter of injury on pod 1 but diminished once again by pod 14. These results were consistent with those observed regarding *Ccr2* expression ([Fig 2I](#pone.0230080.g002){ref-type="fig"}). Most CCR2-positive (CCR2^+^) cells exhibited a round shape and a segmented nucleus. Multiple-staining experiments revealed that CCR2^+^ cells had merged, suggesting that these cells were granulocytes ([Fig 3D](#pone.0230080.g003){ref-type="fig"}). Few-to-no CCR2^+^ reactions were observed in cells stained with Iba1, NeuN, and GFAP. The numbers of CCR2^+^, Ly-6G^+^, and Iba1^+^ cells at the site of injury were 292 ± 32, 394 ± 42, and 27 ± 6 cells/mm^2^, respectively. Moreover, we observed 245 ± 26 cells/mm^2^ CCR2^+^/Ly-6G^+^ cells at the site of injury: a significantly greater number than that of CCR2^+^/Iba1^+^ cells (4 ± 2 cells/mm^2^) ([Fig 3E](#pone.0230080.g003){ref-type="fig"}). Our results also indicated that CCR2^+^/Ly-6G^+^ cells had merged with iNOS^+^ cells (236 ± 21 cells/mm^2^) ([Fig 3F and 3G](#pone.0230080.g003){ref-type="fig"}).

Distribution of CCL5 and CCR5 expression in the spinal cord on day 14 {#sec019}
---------------------------------------------------------------------

We aimed to determine the localization of CCL5 and its receptor. Previous studies have reported that CCL5 binds to three receptors: CCR1, CCR3, and CCR5 \[[@pone.0230080.ref032]\]. Because *Ccr1* and *Ccr3* expression temporarily increased in the acute phase and decreased by pod 7, we focused only on the levels of CCR5, whose underlying gene expression exhibited sustained increases by pod 14 ([Fig 2H, 2J and 2K](#pone.0230080.g002){ref-type="fig"}). Few-to-no CCL5 immunoreactions were observed in the spinal cord immediately following SCI or pod 1. However, CCL5 immunoreactions were observed on pod 14 around the SCI site. The CCL5 immunoreactions merged with NeuN^+^ and F4/80^+^ cells but not with GFAP^+^ cells ([Fig 4A](#pone.0230080.g004){ref-type="fig"}).

![Localization of CCL5 and CCR5 after spinal cord injury (SCI).\
**(A)** CCL5^+^ cells were observed at the peri-injury site on pod 14 and were merged with NeuN^+^ (*red*) and F4/80^+^ (*red*) cells, respectively (arrows). However, CCL5^+^ cells were not merged with GAFP^+^ cells (*red*). **(B)** CCR5^+^ immunoreactivity (*green*) was observed in the epicenter on pod 1, and merged with Ly-6G^+^ cells (*red*) (arrows). **(C)** CCR5^+^ cells (*green*) were observed at the peri-injury site on pod 14, and were merged with NeuN^+^ (*red* with arrows) and F4/80^+^ (arrows with dashed lines) cells. **(D)** F4/80^+^ cells (*red*) on pod 14 co-stained with Ym1^+^ immunoreactions (*green*), a marker for M2-type alternatively activated MG/MΦ (arrows). Nuclei were detected using DAPI.](pone.0230080.g004){#pone.0230080.g004}

Although the immunoreactions were prominent at the epicenter of the injury on pod 1, CCR5 immunoreactivity was rarely observed post-SCI. CCR5^+^ cells exhibited a round shape with lobed nuclei; moreover, similar to the findings observed for CCR2 on pod 1, CCR5^+^ cells were merged with Ly-6G ([Fig 4B](#pone.0230080.g004){ref-type="fig"}). However, unlike the findings for CCR2, CCR5 immunoreactivity was still observed on pod 14 at the peri-injury site. Furthermore, CCR5^+^ cells were merged with NeuN+ and F4/80+ immunoreactions ([Fig 4C](#pone.0230080.g004){ref-type="fig"}) on pod 14. Moreover, the F4/80^+^ cells were co-stained with Ym1, which is an AAM marker ([Fig 4D](#pone.0230080.g004){ref-type="fig"}).

Effects of hMSCs on CCL2, CCR2, and the inflammatory response {#sec020}
-------------------------------------------------------------

We subsequently investigated the effect of hMSC treatment on the levels of gene expression corresponding to chemokines and their receptors. The mouse specificity of the chemokine primers was examined using mouse spinal cords and naïve hMSCs via RT-PCR ([Fig 5A](#pone.0230080.g005){ref-type="fig"}). A house-keeping gene, *Gapdh* (glyceraldehyde-3-phosphate dehydrogenase), primers for which amplified both human and mouse samples gene expression in our previous study \[[@pone.0230080.ref027]\], was recognized signals from both mouse and human samples. However, all tested primers for *Ccl2*, *Ccl5*, and their receptors were amplified with estimated size in mouse spinal cord samples ([Fig 5A](#pone.0230080.g005){ref-type="fig"}). We then compared *Ccl2* levels in the spinal cord between mice injected with HBSS or hMSCs after SCI. *Ccl2* expression on pod 3 was approximately 16-fold higher in mice treated with hMSCs than in those treated with HBSS; these increases remained significant at pod 14 ([Fig 5B](#pone.0230080.g005){ref-type="fig"}). Although levels of *Ccr2* expression in the spinal cord were similar in hMSC- and HBSS-treated mice on pod 3, they increased in hMSC-treated mice by pod 14 ([Fig 5C](#pone.0230080.g005){ref-type="fig"}).

![Human mesenchymal stem/stromal cells (hMSCs) increased *Ccl2* expression and reduced inflammatory responses.\
**(A)** All tested chemokine and receptor primers were detected at the expected rates in mouse samples (Ms). *Ccl2* **(B)** and *Ccr2* **(C)** expressions in the spinal cord were quantified via real time-PCR after spinal cord injury (SCI) and hMSC injection. *Ccl2* levels were significantly increased in hMSC-treated mice (n = 19 mouse) on postoperative days (pod) 3 and 14 relative to the levels observed in HBSS-treated mice (n = 13 mouse) on the same pod. Temporary increases in *Ccr2* expression were observed in HBSS-treated mice, with levels decreasing by pod 14. However, increases in *Ccr2* expression remained significant in hMSC-treated mice on pod 14. Data are expressed as mean ± SEM. \*\*: *P \< 0*.*01* (Dunnett's *post hoc* test), n.s.: not significant. **(D)** CCL2^+^ cells (*green*) were co-labeled with NeuN^+^ cells (*red*) in both groups on pod 3. *Blue* indicates nuclear staining using DAPI. **(E)** Slight CCR2^+^ immunoreactivity (*green*) was observed in Ly-6G^+^ (*pink* with arrows) and Iba1^+^ (arrows with dashed lines) cells. Moreover, some large cells were labeled with CCR2 antibody (arrowhead). *Blue* indicates nuclear staining using DAPI. **(F)** No significant differences in the number of positive cells were observed between the hMSCs- and HBSS-treated groups (n = 3 mouse at each group). **(G)** Large CCR2^+^ cells (*red*; arrows) co-localized with NeuN^+^ reactions (*green*) but not with GFAP^+^ reactions (*pink*). *Blue* indicates nuclear staining using DAPI. **(H-K)** The transplantation of hMSCs influenced inflammation-induced gene expression in the spinal cord on pod 3. Animals treated with hMSCs (n = 10 mouse) exhibited significant decreases in *Il1b* **(H)**, *Elane* **(I)**, and *Mpo* **(J)** expression in the spinal cord on pod 3 relative to HBSS-treated animals (n = 5 mouse). **(K)** Conversely, *Zc3h12a* expression was significantly greater in hMSC-treated mice (n = 9 mouse) than in HBSS-treated mice (n = 8 mouse) on pod 14. The gene expression levels are expressed the relative level (fold) to compare with pod 0 (basal level, n = 6 mouse) after normalization against *Gapdh* as a housekeeping gene. Data are expressed as mean ± SEM. \*: *P \< 0*.*05* (Dunnett's *post hoc* test), n.s.: not significant.](pone.0230080.g005){#pone.0230080.g005}

No obvious differences were observed in CCL2^+^ or CCR2^+^ staining, which had merged with NeuN staining around the site of injury, between the groups on pod 3. However, the intensity of immunoreactivity tended to be greater in mice treated with hMSCs ([Fig 5D](#pone.0230080.g005){ref-type="fig"}). While Ly-6G^+^ cells were easily recognized at the sites of injury, their numbers did not differ significantly between the groups. However, there were few CCR2^+^ cells, and they did not overlap with Ly-6G^+^ cells ([Fig 5E and 5F](#pone.0230080.g005){ref-type="fig"}). On pod 3, CCR2 immunoreactivity was observed in larger cells at the site of injury, overlapping with NeuN^+^ cells ([Fig 5G](#pone.0230080.g005){ref-type="fig"}).

To determine the effect of hMSC treatment on inflammation involving granulocytes, we examined gene expression for inflammatory markers, such as *Il1b*, *Elane* (neutrophil expressed elastase), and *Mpo* (myeloperoxidase) on pod 3. While HBSS-injected SCI mice exhibited an increase in the expression of all three genes in the spinal cord, this expression was significantly suppressed in mice treated with hMSCs ([Fig 5H--5J](#pone.0230080.g005){ref-type="fig"}). *Zc3h112a* (Zinc finger CCCH-type containing 12A, also known as monocyte chemotactic protein-induced protein) is a protein whose expression is induced by CCL2; *Zc3h112a* is thereby implicated in immunosuppression and M2-type macrophage polarization \[[@pone.0230080.ref033]\]. Mice treated with hMSCs exhibited significant increases in *Zc3h112a* expression in the spinal cord on pod 14 ([Fig 5K](#pone.0230080.g005){ref-type="fig"}).

Effects of hMSCs on CCL5 and CCR5 expression {#sec021}
--------------------------------------------

We next investigated the effects of hMSCs on CCL5 and CCR5 at pod 14. We observed no significant differences in the expressions of *Ccl5* or *Ccr5* in the spinal cord between the hMSC- and HBSS-treated groups on pod 3. Although no differences in *Ccr5* expression were observed, *Ccl5* expression in the spinal cord increased by approximately 11-fold in hMSC-treated mice by pod 14 relative to the levels observed in HBSS-treated mice ([Fig 6A and 6B](#pone.0230080.g006){ref-type="fig"}).

![Human mesenchymal stem/stromal cells (hMSCs) increased levels of CCL5 expression during the chronic phase.\
Expression of mouse **(A)** *Ccl5* and **(B)** *Ccr5* in the spinal cord was quantified via real-time PCR in a time-dependent fashion after spinal cord injury (SCI) and hMSC injection. Mice treated with hMSCs (n = 19 mouse) exhibited significant increases in *Ccl5* expression relative to HBSS-treated mice (n = 13 mouse) on postoperative day (pod) 14. However, no significant differences in *Ccr5* expression were observed between the two groups during the experimental period. Data are expressed the relative level (fold) to compare with pod 0 (basal level, n = 6 mouse) after normalization against *Gapdh* as a housekeeping gene. Data are expressed as the mean ± SEM. \*\*: *P \< 0*.*01* (Dunnett's *post hoc* test), n.s.: not significant. **(C)** CCL5 immunoreactivity (*green*) was observed at the peri-injury site on pod 14 and merged with NeuN^+^ (*red*) and F4/80^+^ (*pink*) cells. Mice treated with hMSCs exhibited greater CCL5^+^ immunoreactivity than did HBSS-treated mice. **(D)** Similar CCR5^+^ reactions (*green*) were merged with F4/80^+^ (*red*) cells in both experimental groups. *Blue* indicates nuclear staining using DAPI.](pone.0230080.g006){#pone.0230080.g006}

Immunostaining experiments confirmed that CCL5 merged with NeuN^+^ and F4/80^+^ cells ([Fig 3](#pone.0230080.g003){ref-type="fig"}). However, the CCL5^+^/F4/80^+^ cells were more dominant in hMSC-treated mice ([Fig 6C](#pone.0230080.g006){ref-type="fig"}). In hMSCs-treated mice, CCR5^+^ cells were merged with F4/80^+^ cells around the site of injury ([Fig 6D](#pone.0230080.g006){ref-type="fig"}).

Influence of hMSCs on MG/MΦ polarization {#sec022}
----------------------------------------

Injection of hMSCs on pod 1 influenced MG/MΦ levels on pod 14. Quantification experiments revealed that hMSC-treated animals exhibited significantly greater *Aif1* (a pan-MG/MΦ marker, also known as Iba1) expression than did HBSS-treated animals on pod 14 ([Fig 7A](#pone.0230080.g007){ref-type="fig"}). Immunostaining for Iba1 in the spinal cord revealed that Iba1^+^ reactions clustered at both the peri-injury and injection sites in hMSC-treated mice; no such clustering was observed around the site of injection in the HBSS-treated group ([Fig 7B](#pone.0230080.g007){ref-type="fig"}). Fluorescent staining revealed that F4/80^+^ MG/MΦ-like cells were co-expressed with Ym1^+^ cells around the injection site, suggestive of M2-type AAMs ([Fig 7C](#pone.0230080.g007){ref-type="fig"}). Moreover, the number of F4/80^+^ MG/MΦ-like cells was greater in hMSC-treated mice than in HBSS-treated mice.

![Human mesenchymal stem/stromal cells (hMSCs) increased levels of alternatively activated macrophages (AAM) and anti-inflammatory cytokines.\
**(A)** The transplantation of hMSCs significantly increased the levels of *Aif1* expression on postoperative day (pod) 14 (n = 9 mouse) relative to those observed in the HBSS-treated animals (n = 8 mouse). Data are expressed as the mean ± SEM. \*\*: *P \< 0*.*01* (Dunnett's *post hoc* test), n.s.: not significant. **(B)** Iba1-positive MG/MΦ were clustered around the site of hMSC injection on pod 14 (n = 3 mouse in each group). **(C)** F4/80^+^ cells (*green*) exhibited greater overlap with Ym1^+^ cells (*red*) around the injection site in the hMSC-treated group than in the HBSS-treated group. Nuclear staining was performed using DAPI. Transplantation of hMSCs significantly increased the expression of the AAM markers *Arg1* **(D)** and *Chil3* **(E)**, as well as that of the anti-inflammatory cytokine *IL-4* **(F)** on pod 14. All data are expressed the relative level (fold) to compare with pod 0 (basal level, n = 6 mouse) after normalization against *Gapdh* as a housekeeping gene. Data are expressed as the mean ± SEM. \*: *P\<0*.*05*, \*\*: *P \< 0*.*01* (Dunnett's *post hoc* test), n.s.: not significant.](pone.0230080.g007){#pone.0230080.g007}

Expression of the AAM markers *Arg1* (*Arginase1*) and *Chil3*, which encodes Ym1, was significantly lower in the hMSCs-treated group than in the HBSS-treated group on pod 3. However, levels of gene expression had increased by 15- and 2-fold, respectively, in the hMSCs-treated group on pod 14 ([Fig 7D and 7E](#pone.0230080.g007){ref-type="fig"}). Moreover, the expression of the anti-inflammatory cytokine *IL-4* had increased by 3-fold in hMSCs-treated animals by pod 14 ([Fig 7F](#pone.0230080.g007){ref-type="fig"}).

Influence of hMSCs on axonal regeneration {#sec023}
-----------------------------------------

To determine the effect of hMSCs on axonal regeneration, we examined gene expression and protein localization corresponding to CRMP2 (encoded by *Dpysl2*) and GAP43 in the mouse spinal cord after SCI. Expression of *Dpysl2* remained nearly unchanged in HBSS-treated mice during the experimental period. However, *Dpysl2* expression increased on pod 14 and was significantly higher in hMSC-treated mice than in HBSS-treated mice ([Fig 8A](#pone.0230080.g008){ref-type="fig"}). Similar tendencies were observed for *Gap43* expression, which was significantly higher in hMSCs-treated animals on pod 14 ([Fig 8B](#pone.0230080.g008){ref-type="fig"}). CRMP2^+^ and GAP43^+^ immunoreactions were detected in the peri-injury region and clearly merged with NeuN^+^ neurons on pod 14 ([Fig 8C and 8D](#pone.0230080.g008){ref-type="fig"}).

![Human mesenchymal stem/stromal cells (hMSCs) promoted axonal regeneration.\
The transplantation of hMSCs increased the expression of the axonal regeneration markers *Dpysl2* **(A)** and *Gap43* **(B)**. Mice treated with hMSCs (n = 9 mouse) exhibited significantly greater gene expression than did the HBSS-treated mice (n = 8 mouse) on postoperative day (pod) 14. All data are expressed the relative level (fold) to compare with pod 0 (basal level, n = 6 mouse) after normalization against *Gapdh* as a housekeeping gene. Data are expressed as the mean ± SEM. \*: *P \< 0*.*05* (*Student's t*-test), n.s.: not significant. **(C)** CRMP2 immunoreactivity (*green*) was observed in NeuN^+^ neurons (*red*) at the peri-injury site on pod 14. **(D)** GAP43 immunoreactivity (*green*) was merged with NeuN^+^ neurons (*red*) at the peri-injury site on pod 14 (n = 3 mouse in each group). *Blue* indicates nuclear staining using DAPI.](pone.0230080.g008){#pone.0230080.g008}

CCL5 promotes AAM activity and axonal regeneration {#sec024}
--------------------------------------------------

To confirm whether increases in *Ccl5* expression following hMSC injection contribute to MG/MΦ polarization and axonal regeneration, mouse recombinant CCL5 was injected into the spinal cord after SCI on pod 7. On the following day, we examined the gene expression of AAM and axonal regeneration markers. *Aif1* expression remained unchanged following CCL5 injection ([Fig 9A](#pone.0230080.g009){ref-type="fig"}). However, CCL5-treated mice tended to increase the expression of *Chil3* and *Arg1* and exhibited significantly greater *Chil3* expression than did vehicle-treated mice (*p* = 0.004) ([Fig 9B and 9C](#pone.0230080.g009){ref-type="fig"}), suggesting that CCL5 contributes to MG/MΦ polarization.

![Microglia/macrophage (MG/MΦ) polarization and axonal regeneration were enhanced by CCL5.\
To determine whether increases in CCL5 following hMSC transplantation contribute to MG/MΦ polarization and axonal regeneration, recombinant mouse CCL5 (rmCCL5, n = 6 mouse) or vehicle (n = 6 mouse) was injected into the spinal cord on postoperative day (pod) 7. We examined levels of gene expression for MG/MΦ polarization **(A-C)** and axonal regeneration **(D and E)** 24 hours after injection. There were no obvious differences in the levels of the pan-macrophage marker *Aif1* **(A)**. Expression of the M2-type AAM marker *Chil3* **(B)** significantly increased following the injection of rmCCL5 (*p\<0*.*01*). Although *Arg1* expression **(C)** also tended to increase, these increases were nonsignificant. Expression of the axonal regeneration marker *Gap43* **(E)** significantly increased following the injection of rmCCL5 (*p\<0*.*05*), while *Dpysl2* **(D)** expression tended to increase (*p = 0*.*097*). All data are expressed the relative level (fold) to compare with vehicle treated animals (n = 6 mouse) after normalization against *Gapdh* as a housekeeping gene. Data are expressed as the mean ± SEM. \*\*: *P \< 0*.*01*, \*: P \< 0.05 (Dunnett's *post hoc* test).](pone.0230080.g009){#pone.0230080.g009}

CCL5-injected mice also exhibited increases in *Dpysl2* (*p* = 0.097) and *Gap43* (*p* = 0.033) expression ([Fig 9D and 9E](#pone.0230080.g009){ref-type="fig"}), suggesting that CCL5 also contributes to axonal regeneration.

Discussion {#sec025}
==========

Human-MSC therapy has shown promise in supporting regeneration and/or recovery from diverse tissue injuries, including neuronal injuries \[[@pone.0230080.ref003]--[@pone.0230080.ref006]\]. Although we have reported that implanted hMSCs suppress neural injuries in mice by modulating MG/MΦ after brain ischemia and SCI \[[@pone.0230080.ref007], [@pone.0230080.ref008]\], the mechanism and form of communication between hMSCs and MG/MΦ remain unclear. In the present study, we examined the influences of hMSCs on chemokine expressions because chemokines guide the migration of immune cells, including MΦ. Using our SCI model, we especially focused on hMSC-induced changes in two MΦ-related chemokine axes: CCL2/CCR2 and CCL5/CCR5. We here xenografted hMSCs into mouse spinal cord without administration of immunosuppressants to not influence an immune response. Many studies were given immunosuppressants for decrease of the rejection by xenografting. However, we have previously reported that injection of the hMSCs into immunocompetent mouse brain did not change the fate of cells to compare with immunodeficient mice \[[@pone.0230080.ref008]\]. These are supported and reproduced by many studies \[[@pone.0230080.ref010]\].

The *Ccl2* and *Ccr2* expressions drastically increased on pod1, and CCL2^+^ immunoreactions were recognized in neurons in the acute phase following SCI. While previous studies have reported that CCR2 is mainly expressed in monocytes and infiltrated MΦ \[[@pone.0230080.ref034]\], CCR2^+^ reactions had barely merged with F4/80^+^ MG/MΦ; however, CCR2^+^ reactions overlapped greatly with Ly-6G^+^ granulocytes, which were likely neutrophils, at the epicenter of the injury on pod 1. Aberrations in the CCL2/CCR2 axis are reportedly associated with neuroinflammatory disease. \[[@pone.0230080.ref035]--[@pone.0230080.ref039]\]. CCR2 gene-deficient (KO) animals exhibit decreases in lesion size and recruitment of monocytes into the lesion following traumatic brain injury (TBI) \[[@pone.0230080.ref018]\] and SCI,\[[@pone.0230080.ref040]\]. Moreover, CCR2^+^ neutrophils are activated under inflammatory conditions, thereby exacerbating the inflammatory response \[[@pone.0230080.ref041], [@pone.0230080.ref042]\]. According to these studies, most CCR2^+^/Ly-6G^+^ granulocytes on pod 1 exhibited co-localization of iNOS, suggesting an increase of inflammation.

In the present study, the hMSC implantation resulted in improvements in locomotor activity and tended to decrease lesion size; these findings were consistent with our previous report \[[@pone.0230080.ref007]\]. While we initially expected that the implanted hMSCs would diminish *Ccl2* expression, the levels of *Ccl2*, and not those of *Ccr2*, increased following hMSC transplantation. However, the numbers of Ly-6G^+^ and CCR2^+^/Ly-6G^+^ cells did not change significantly with hMSC transplantation. Interestingly, CCR2^+^ immunoreactions after hMSC transplantation were observed in NeuN^+^-neurons as well as Ly-6G^+^ cells.

Some recent studies have speculated that, in addition to its role in chemotaxis, CCL2 exerts neuroprotective and immunomodulatory effects \[[@pone.0230080.ref018], [@pone.0230080.ref019]\]. CCL2 aids in the migration of neural precursor cells and promotes neuroregeneration in patients with TBI \[[@pone.0230080.ref039]\] and stroke \[[@pone.0230080.ref043]\]. Kwon *et al*. suggested that the overexpression of CCL2 derived from neurons promotes axonal regeneration via AAM activation after CNS injury \[[@pone.0230080.ref044]\]. Investigating the condition of inflammation and neutrophil activation, we found that the transplantation of hMSCs decreased the gene expression levels of *Il1b*, *Elane* and *Mpo*; these observations indicated reduced inflammation and neutrophil activation. Recent findings are consistent with our results: neutrophils polarized after infiltration can exert both beneficial and deleterious effects following tumorigenesis \[[@pone.0230080.ref045]--[@pone.0230080.ref047]\], stroke \[[@pone.0230080.ref048]\] and TBI \[[@pone.0230080.ref049]\]. Further, we found that mice treated with hMSCs exhibited persistent *Ccl2* expression for 2 weeks as well as increases the expression of *Zc3h12a*, which encodes MCPIP1 and is known to induce by CCL2 and IL-1β, on pod14. MCPIP1 plays a role in anti-inflammation via the down-regulation of NF-κB signaling \[[@pone.0230080.ref050]\], and MCPIP1-KO mice reportedly exhibit significant increases in infarct volume after brain ischemia \[[@pone.0230080.ref051]\]. Although further studies are required to determine the precise roles of chronic increases in CCL2, the enhancement of *Ccl2* expression via hMSC transplantation may contribute to anti-inflammation.

We also examined the expression of *Ccl5* after inducing SCI: it drastically increased by pod 14. While CCL5 binds to three receptors, CCR1, CCR3, and CCR5, we focused on CCR5 because *Ccr5* expression remained significantly elevated through pod 14. Our findings vary in their consistency with previous research, as the role of the CCL5/CCR5 axis in CNS injuries is controversial in the literature. CCL5 deletion reduces infarct volume in cerebral ischemia \[[@pone.0230080.ref052]\], and CCR5 blockade improves locomotor function in a murine model of SCI \[[@pone.0230080.ref053]\]. These observations suggest that CCL5 acts as a deleterious chemokine. Conversely, CCR5-KO mice exhibit increases in infarct volume in models of ischemia \[[@pone.0230080.ref054]\] and accelerated motor neuronal death in models of hypoglossal nerve injury \[[@pone.0230080.ref055]\]. Application of CCL5 to cultured neural cells significantly suppressed cell death and increased the expression of some growth factors \[[@pone.0230080.ref021]\]. Moreover, CCL5 decreased IL-1β, IL-6, tumor necrosis factor alpha (TNF-α), and iNOS gene expression in lipopolysaccharide-treated primary MG cultures \[[@pone.0230080.ref055]\].

The present study found that the hMSC implantation significantly increased *Ccl5* expression by pod 14 but observed no changes in *Ccr5* expression. Previous investigations have reported that CCL5 expression in neurons, MΦ, and astrocytes of the spinal cord of models of neuropathic pain and ischemia increased from pod 3 \[[@pone.0230080.ref021], [@pone.0230080.ref056]\]. We observed that CCL5 and CCR5 localized to neurons and MG/MΦ; this was not affected by hMSC implantation. However, the intervention increased the expressions of pan-MG/MΦ (*Aif1*) and M2-type AAM (*Arg1* and *Chil3*) markers. Moreover, the animals that received the hMSC implantation exhibited increases in *Il4* expression by pod 14. IL-4 is a major activator of AAM polarization \[[@pone.0230080.ref057]\]. Interestingly, CCL2, CCL5, and insulin-like growth factor 1 (IGF-1) are also reportedly involved in the differentiation of MG/MΦ toward AAMs in osteoblasts \[[@pone.0230080.ref024]\], suggesting that greater hMSC-induced *Il4* and *Ccl5* expression by might stimulate MG/MΦ migration and polarization.

Axonal extension and reconstruction of neuronal networks are important events in the recovery of spinal function. Research has suggested that AAMs promote axonal growth and overcome the effects of inhibitory substrates \[[@pone.0230080.ref058]\]. Several studies have also indicated that the implantation of AAMs into the injured spinal cord induces axonal regrowth and functional improvement \[[@pone.0230080.ref059], [@pone.0230080.ref060]\]. In the present study, implantation of hMSCs increased the expression of the genes encoding axonal regenerative markers, including *Dpysl2* and *Gap43*, on pod 14, and corresponding immunoreactions were observed in the neurons at the peri-injury site. To obtain direct evidence for the contribution of the increased *Ccl5* expression to axonal extension, we injected rmCCL5 into the spinal cord on pod 7 and determined the gene expression of M2-type AAM as well as the levels of axonal regenerative markers. We observed significantly greater *Chil3* and *Gap43* expression in rmCCL5-treated mice, which also tended to exhibit increases in *Arg1* and *Dpysl2* expression; however, no obvious changes in *Aif1* expression were observed following CCL5 injection. These results suggest that the CCL5 may partially participate in AAM polarization and axonal extension.

In the present study, we examined the role of hMSCs after SCI by focusing on two representative MΦ-related chemokine axes, CCL2/CCR2 and CCL5/CCR5, both of which exhibited acute or chronic increases following SCI. hMSC implantation upregulated the levels of these chemokines. We also confirmed improvements in the clinical symptoms of SCI following hMSC injection. While the CCL2/CCR2 axis contributes to the enhancement of inflammation, hMSC-mediated increases in CCL2 did not alter the number of granulocytes. Moreover, hMSCs might induce MG/MΦ polarization to the M2-type AAM and drive axonal generation. While chemokines could participate in these functions, the direct mechanisms by which the communication between hMSCs and the recipient tissues yield these phenomena remain to be elucidated. Future studies should examine mice subjected to chemokine KO or gene silencing to determine whether hMSCs influence CCL2/CCR2 and CCL5/CCR5 axes in post-SCI neuroregeneration.

Conclusions {#sec026}
===========

In conclusion, the post-SCI implantation of hMSCs enhances the expression of *Ccl2* and *Ccl5* and improves locomotor activity. Moreover, the implantation of hMSCs enhances MG/MΦ polarization to AAM and the gene expression of axonal regenerative markers. The function of hMSCs might be partially mediated by the chemokine axes.
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Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript if you think you can satisfactorily addresses the points raised during the review process.

In addition to the concerns from reviewer 1 (see details below), please address following:

1\. Provide evidence that hMSCs are present at the injection site

2. What is the survival rate and where are they located if they are not at the injury site

3. Why are there no dendrites on neurons?

We would appreciate receiving your revised manuscript by Jan 27 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>
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A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.
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The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.
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2\. Has the statistical analysis been performed appropriately and rigorously?
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4\. Is the manuscript presented in an intelligible fashion and written in standard English?
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Reviewer \#1: Human bone marrow-derived mesenchymal stem/stromal cell (hMSC) transplantation is a promising strategy for improving functional recovery following traumatic spinal cord injury (SCI). However, the mechanism behind the integration of hMSCs and their beneficial effects remains elusive. The authors seek to 1) transcriptionally characterize the role of microglia/macrophages after SCI; 2) identify the cellular localization of CCL2/CCR2 and CCL5/CCR5 chemokine systems; 3) assess the role of hMSCs on CCL2/CCR2 and CCL5/CCR5; and 4) validate the role of CCL5 administration on microglia/macrophages polarization. The authors suggest that hMSCs increase CCL2 and CCL5 expression, increase gene expression of axonal regenerative markers, and increase microglia/macrophage polarization toward the alternatively activated phenotype.
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• The representation of expressional changes in Figure 1 needs to be revised. Line graphs or heatmaps would be more suitable for representing time-course transcriptional differences. How was the absolute PCR analysis performed?

• The functional recovery assessment is singular (relies only on BMS scores) and is terminated at 14 days while the difference between the treatment is continuing to deviate. The authors need to provide a justification for not continuing their analyses to the chronic phase.

• The authors need to indicate how their transcriptional work in Figure 1 advances the previous studies performing transcriptional analyses in SCI research.

• It's not clear to the reader why the authors refrained from administration of immunosuppressants or immunodeficient animals, particularly considering the low survival of hMSCs following transplantation.

Minor Comments:

• The authors need to justify their choice for using a transection model for studying immune cell migration.
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• Line 25: "Central" should not be capitalized.
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6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]
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Author response to Decision Letter 0

2 Jan 2020

Thank you very much for the academic editor's and reviewer's comments to improve our manuscript of paper (PONE-D-19-28233). We read the comments well, and answered and revised according to your suggestions. We also removed all the term "data not shown" as journal requirements.

Comments from editor

1\. Provide evidence that hMSCs are present at the injection site

2\. What is the survival rate and where are they located if they are not at the injury site

Thank you very much for your comments. We thought that the comments 1 and 2 linked each other. So, we answered them together.

Injected hMSCs were disappeared quickly from the injective site. However, it is known to rescue several diseases (Prockop DJ. Clin Pharmacol Ther. 2007; <https://ascpt.onlinelibrary.wiley.com/doi/full/10.1038/sj.clpt.6100313>).

Also. in present study, we determined the fate of hMSCs using human GAPDH mRNA (hGAPDH) expression in the mouse spinal cord by real-time PCR (Fig. 1A). The estimate number of hMSCs was calculated by standard curve of the gene expression. Standard curves were generated by adding serial dilutions of hMSCs (1 × 102 to 1 × 106 cells) to spinal cord samples (T7 to T12 vertebrae) of uninjured mice prior to homogenization (see page 13, line 95\~).

We have also reported previously the retention of hMSCs by hAlu genomic DNA expression and the localization of PKH26-labeled hMSCs by immunohistochemistry in same animal model (Fig. 2 in Tsumuraya et al. J Neuroinflammation 2015; <https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-015-0252-5>). We showed in the study that the injected hMSCs are seen to have migrated along the spinal cord toward the injury site at 7 days after SCI.

The fate of hMSCs in the present study was shown in Fig. 1A. Immediately after hMSC injection (pod 1), approximately 260,000 hMSCs were detected (representing 50% of the injected cells) including the site of injection. The numbers of hMSCs decreased to approximately 40,000 cells on pod 3(15% of pod1), and have few-to-no hMSCs were detected on pod 14 (see page 21, line 10\~). The reason, we choose hGAPDH, but not hAlu in present study is to eliminate a possibility of genomic DNA from hMSCs debris although the result was almost similar with previously.

We have reported the fate of hMSCs in our other studies of brain ischemia (Ohtaki et al. Proc Natl Acad Sci U S A. 2008; <https://www.pnas.org/content/105/38/14638.long>) and STZ-induced diabetes (Murai et al. PLoS One 2017; <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0186637>). These studies also support in the present results.

The question of "where are they located if they are not at the injury site" is very difficult to answer. In the present study, the cells as the hGAPDH level almost disappeared from the spinal cord on pod 14. The cells might eliminate by phagocytes and/or move to somewhere. We have examined the distribution of hMSCs in systemic organs by an in vivo fluorescence imager (Murai et al. PLoS One 2017). However, the detection of small amount of cells was extremely difficult. So, I am sorry we do not have accurate answer of this.

3\. Why are there no dendrites on neurons?

In present study, we used anti-Neu N antibody as a neuronal marker. Neu N is known to be stained neuronal nuclei and the peri-nucleic region (nerve cell body), but not or few in fibers. So the staining of neurons seems to round and triangle sometimes.

Comments to reviewer

Thank you very much for your supportive comments. We revised our manuscript (indicated yellow highlight in the text) and commented to you below.

Major Comments:

1\. The main objective of the study needs to be clearly indicated and experiments need to coherently follow the main objective. How were the genes selected for the PCR experiment? Why choose CCL2/CCR2 and CCL5/CCR5?

In present study was designed according to our previous studies. We have focused on the communication between transplanted hMSCs and microglia/macrophages (MG/MΦ) on SCI. Therefore, we firstly selected mainly the MG/MΦ including monocyte-related chemokines and the receptors. Then, from expressing pattern we further focused on the CCL2/CCR2 and CCL5/CCR5. CCL5/CCR5 is a chemokine and receptors increased at chronic periods. Although many chemokines (receptors) increased at acute periods, we selected the most popular MG/MΦ-related chemokine CCL2/CCR2 axis. We think that we should examine the other chemokines in the future study.

Although this is unpublished data, we are recognizing in another project that CCL2/CCR2 axis is an important signal to communicate hMSCs and recipient cells. Would you wait for wait a little more to reveal our next publication?

2\. The representation of expressional changes in Figure 1 needs to be revised. Line graphs or heatmaps would be more suitable for representing time-course transcriptional differences. How was the absolute PCR analysis performed?

Thank you very much. We revised bar to line graphs in Fig.1 (now, this is Fig.2). Moreover, we have not described the unit in the text including the legend and graphs clearly. They are relative level (fold) to compare with day 0. This mentioned in the methods section (see page 14 line 125\~) and figure legend. As described below, we reconsidered the order of the figures from your comment \#3. Fig.1 in original manuscript changed to Fig.2.

3\. The functional recovery assessment is singular (relies only on BMS scores) and is terminated at 14 days while the difference between the treatment is continuing to deviate. The authors need to provide a justification for not continuing their analyses to the chronic phase.

We have reported injection of hMSCs suppress neural injury through the macrophage or microglial modulation in the acute phase (within a week) after ischemia (Ohtaki et al. Proc Natl Acad Sci U S A. 2008). Moreover, the phenomenon has been reproduced after SCI as well (Tsumuraya et al. J Neuroinflammation 2015). Therefore, we decided the experiment periods based on the previous our studies and checked the reproducibility by BMS and gene expression of neuron specific enolase (Eno2) in the present study. However, we thought your comments also very reasonable if we showed figures in present order. We reconsidered again the order of the figures. We inserted Fig. 4 prior to Fig. 1 to be logically. Thank you for your supportive comments.

4\. The authors need to indicate how their transcriptional work in Figure 1 advances the previous studies performing transcriptional analyses in SCI research.

Yes. Some of SCI studies have reported to the gene expression of chemokines. However, we have not determined the expressions in this model so far. Therefore, we did them.

5\. It's not clear to the reader why the authors refrained from administration of immunosuppressants or immunodeficient animals, particularly considering the low survival of hMSCs following transplantation.

Thank you for your comments. As your suggestion, many studies administer administration of immunosuppressants or use immunodeficient animals. However, to observe inflammation or immune systems, we were afraid that they might interfere to the systems. We have previously examined injection of hMSCs into brain parenchyma and compared the fate of hMSCs between immunodeficient and immunocompetent animals. Resulting, no significant differences were recognized (Ohtaki et al. Proc Natl Acad Sci U S A. 2008). Moreover, repetitive injections of hMSCs into immunocompetent animals did not show any anaphylactic reactions or die (Murai et al. PLoS One 2017). The following manuscript explain the reason to inject hMSCs into immunocompetent animals. We added this in our references.

Prockop DJ, Oh JY, Lee RH. Data against a Common Assumption: Xenogeneic Mouse Models Can Be Used to Assay Suppression of Immunity by Human MSCs. Mol Ther. 2017 2;25(8):1748-1756. doi: 10.1016/j.ymthe.2017.06.004.

Minor Comments:

6\. The authors need to justify their choice for using a transection model for studying immune cell migration.

To compare with contusion model, the transection model is localized the injury to a small region. Therefore, we thought to be clear cell-cell communications. Moreover, as the other reason, we continuously studied SCI using this model and there are some evidences for the model.

7\. The abstract needs to be reorganized and compressed. While the authors are informative and descriptive, they should succinctly describe their major findings and main inferences.

Thank you. We revised.

8\. Line 25: "Central" should not be capitalized.

Thank you. We revised.
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Dear Dr Ohtaki,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points (details below).

We would appreciate receiving your revised manuscript by Mar 13 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Xing-Ming Shi, Ph.D

Academic Editor

PLOS ONE
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The manuscript is much improved. However, grammar mistakes and the writing style at the end of the introduction should be addressed. Additionally, the authors may want to mention the justification for the transection model and not administering immunosuppressants in the discussion.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Thank you very much for the academic editor's and reviewer's comments to improve our manuscript of paper (PONE-D-19-28233). We read the comments well, and revised according to your suggestions.

Comments to reviewer

1\. The manuscript is much improved. However, grammar mistakes and the writing style at the end of the introduction should be addressed. Additionally, the authors may want to mention the justification for the transection model and not administering immunosuppressants in the discussion.

Thank you very much for your supportive comments. We revised our manuscript (indicated yellow highlight in the text) according to your comments.

Moreover, we checked entire of manuscript again and slightly changed the order of references.
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Dear Dr. Ohtaki,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Xing-Ming Shi, Ph.D

Academic Editor

PLOS ONE
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Dear Dr. Ohtaki:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr Xing-Ming Shi

Academic Editor

PLOS ONE
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